We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Future of Healthcategory Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest July 30, 2024 Businesscategory Shares of Japan's Eisai tumble after EU rejects ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

This website uses cookies to improve your experience. By continuing to use this website you are accepting our cookie policy. Some cookies are necessary to make the website work properly, for example ...

From the iconic slip dress to those worn-in thrifted fashions, the 90s gave the world several style sounds and the world listened. A major trend that speaks to that decade, but also aligns with the ...

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...

Only a handful of UK hotel chains earned more than three stars for value for money in our most recent survey. With hotel prices rising 13% in the past year, even a poky room in a budget chain with ...

Chicken tenders are a popular item at many fast-food chains; some chains have even built their entire business off them. Todd Graves, for example, turned his idea for a chicken-finger restaurant ...

WASHINGTON — The Space Force’s primary acquisition command has established a new effort to build integrated command and control (C2) networks — that is, machine-to-machine capabilities to ...

For the drugmaker Eisai, the trial was a shot at a windfall — potentially billions of dollars — for defanging a disease that had confounded researchers for more than a century. To assess the ...

Japanese drugmaker Eisai has teamed up with UK biotech Wren Therapeutics on an R&D programme seeking drugs for neurodegenerative disorders. The two companies will focus their efforts on alpha ...